{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:08:26Z","timestamp":1793891306365,"version":"4.8.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"DOI":"10.1215\/s1152851704000869","type":"journal-article","created":{"date-parts":[[2005,7,3]],"date-time":"2005-07-03T21:22:03Z","timestamp":1120425723000},"page":"246-253","source":"Crossref","is-referenced-by-count":125,"title":["Phase 2 trial of copper depletion and penicillamine as antiangiogenesis\ntherapy of glioblastoma"],"prefix":"10.1093","volume":"7","author":[{"given":"Steven","family":"Brem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"New","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surasak","family":"Phuphanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane B.","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,7,1]]},"reference":[{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Alpern-Elran, H., and Brem, S. (1985) Angiogenesis in\nhuman brain tumors: Inhibition by copper depletion. Surg.\nForum36,498\n-500.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Bagley, R.G., Walter-Yohrling, J., Cao, X., Weber, W., Simons, B.,\nCook, B.P., Chartrand, S.D., Wang, C., Madden, S.L., and Teicher, B.A.\n(2003) Endothelial precursor cells as a model of tumor\nendothelium: Charac terization and comparison with mature endothelial cells.\nCancer Res.63,5866\n-5873.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Barker, F.G., 2nd, Chang, S.M., Larson, D.A., Sneed, P.K., Wara,\nW.M., Wilson, C.B., and Prados, M.D. (2001) Age and radiation\nresponse in glioblastoma multiforme. Neurosurgery49,1288\n-1298.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Bauer, K.S., Dixon, S.C., and Figg, W.D. (1998)\nInhibition of angiogenesis by thalidomide requires metabolic activation, which\nis species-dependent. Biochem. Pharmacol.55,1827\n-1834.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F.,\nScaglione, F., Landre, J., Pluderi, M., Tomei, G., Villani, R., Carroll, R.S.,\nBlack, P.M., and Bikfalvi, A. (2001) Low-dose chemotherapy\ncombined with an antiangiogenic drug reduces human glioma growth in vivo.\nCancer Res.61,7501\n-7506.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Brat, D.J., Castellano-Sanchez, A., Kaur, B., and Van Meir, E.G.\n(2002) Genetic and biologic progression in astrocytomas and their\nrelation to angiogenic dysregulation. Adv. Anat.\nPathol.9,24\n-36.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Brem, H., Ehrlich, P., Tsakayannis, D., and Folkman, J.\n(1997) Delay of wound healing by the angiogenesis inhibitor\nTNP-470. Surg. Forum48,714\n-716.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Brem, S. (2004) Angiogenesis and brain tumors. In:\nWinn, H.R. (Ed.), Youmans Neurological Surgery.\nPhiladelphia: Saunders, pp. 771-789.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Brem, S., and Wotoczek-Obadia, M. (2001) Potential\nsynergistic effect of copper reduction, anti-angiogenesis therapy and\ncytotoxic chemother apy (BCNU) in a rat brain tumor model. Proc.\nAm. Assoc. Cancer Res.42,582p\n (abstract 3123).","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Brem, S., Cotran, R., and Folkman, J. (1972) Tumor\nangiogenesis: A quan titative method for histologic grading. J.\nNatl. Cancer Inst.48,347\n-356.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Brem, S.S., Zagzag, D., Tsanaclis, A.M., Gately, S., Elkouby, M.P.,\nand Brien, S.E. (1990a) Inhibition of angiogenesis and tumor\ngrowth in the brain. Suppression of endothelial cell turnover by penicillamine\nand the depletion of copper, an angiogenic factor. Am. J.\nPathol.137,1121\n-1142.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Brem, S., Tsanaclis, A.M., and Zagzag, D. (1990b)\nAnticopper treatment inhibits pseudopodial protrusion and the invasive spread\nof 9L gliosar coma in the rat brain. Neurosurgery26,391\n-396.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Carmeliet, P., and Jain, R.K. (2000) Angiogenesis in\ncancer and other dis eases. Nature407,249\n-257.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Coates, R.J., Weiss, N.S., Daling, J.R., Rettmer, R.L., and\nWarnick, G.R. (1989) Cancer risk in relation to serum copper\nlevels. Cancer Res.49,4353\n-4356.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Cox, D.R. (1972) Regression models and life tables.\nJ. R. Stat. Soc. B.34,187\n-220.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Davis, F.G., Freels, S., Grutsch, J., Barlas, S., and Brem, S.\n(1998) Survival rates in patients with primary malignant brain\ntumors stratified by patient age and tumor histological type: An analysis\nbased on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.\nJ. Neurosurg.88,1\n-10.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"DeVore, R.F., Fehrenbacher, L., Herbst, R.S., Langer, C.J., Kelly,\nK., Gau dreault, J., Holmgren, E., Novotny, W.F., and Kabbinavar, F.\n(2000) A randomized phase II trial comparing rhuMAb VEGF\n(recombinant humanized monoclonal antibody to vascular endothelial cell growth\nfactor) plus carboplatin\/paclitaxel (CP) to CP alone in patients with stage\nIIIb\/IV NSCLC. Proc. Am. Soc. Clin. Oncol.19, 485a (abstract\n1896).","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Diez, M., Cerdan, F.J., Arroyo, M., and Balibrea, J.L.\n(1989) Use of copper\/zinc ratio in the diagnosis of lung cancer.\nCancer63,726\n-730.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Fine, H.A., Figg, W.D., Jaeckle, K., Wen, P.Y., Kyritsis, A.P.,\nLoeffler, J.S., Levin, V.A., Black, P.M., Kaplan, R., Pluda, J.M., and Yung,\nW.K. (2000) Phase II trial of the antiangiogenic agent\nthalidomide in patients with recurrent high-grade gliomas. J. Clin.\nOncol.18,708\n-715.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Fine, H.A., Wen, P.Y., Maher, E.A., Viscosi, E., Batchelor, T.,\nLakhani, N., Figg, W.D., Purow, B.W., and Borkowf, C.B. (2003)\nPhase II trial of thalidomide and carmustine for patients with recurrent\nhigh-grade gliomas. J. Clin. Oncol.21,2299\n-2304.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Godard, S., Getz, G., Delorenzi, M., Farmer, P., Kobayahsi, H.,\nDesbaillets, I., Nozaki, M., Diserens, A.C., Hamou, M.F., Dietrich, P.Y.,\nRegli, L., Janzer, R.C., Bucher, P., Stupp, R., de Tribolet, N., Domany, E.,\nand Hegi, M.E. (2003) Classification of human astrocytic gliomas\non the basis of gene expression: A correlated group of genes with angiogenic\nactivity emerges as a strong predictor of subtypes. Cancer\nRes.63,6613\n-6625.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Grossman, S.A., and Batara J. (2004) Current\nmanagement of glioblastoma multiforme. Semin. Oncol.31,635\n-644.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Grossman, S.A., Carson, K., Piantadosi, S. and Fisher, J.\n(2002) Survival of adults with newly diagnosed\nglioblastoma multiforme (GBM) treated with experimental agents and delayed\nradiation therapy (RT) versus experimental agents and immediate radiation: The\nexperience of the NABTT CNS consortium. Presented at the American\nSociety of Clini cal Oncology Annual Meeting, Orlando, Florida, May 18-21\n(abstract 282). Available at:\nhttp:\/\/www.asco.org.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Hourani, B.T., and Demopoulos, H.B. (1969) Inhibition\nof S-91 mouse melanoma metastases and growth by d-penicillamine.\nLab. Invest.21,434\n-438.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Hu, G.F. (1998) Copper stimulates proliferation of\nhuman endothelial cells under culture. J. Cell\nBiochem.69,326\n-335.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T.,\nHainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E.,\nFerrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F.\n(2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin\nfor metastatic colorectal cancer. N. Engl. J. Med.350,2335\n-2342.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Jain, R.K. (2001) Normalizing tumor vasculature with\nanti-angiogenic ther apy: A new paradigm for combination therapy.\nNat. Med.7,987\n-989.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Jong-Hon, K., Togashi, Y., Kasai, H., Hosokawa, M., and Takeichi,\nN. (1993) Prevention of spontaneous hepatocellular carcinoma in\nLong-Evans cinnamon rats with hereditary hepatitis by the administration of\nd-penicillamine. Hepatology18,614\n-620.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Joyce, D.A. (1989) d-Penicillamine\npharmacokinetics and pharmacody namics in man. Pharmacol.\nTher.42,405\n-427.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J.,\nNovotny, W.F., Lieberman, G., Griffing, S., and Bergsland, E.\n(2003) Phase II, randomized trial comparing bevacizumab plus\nfluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic\ncolorectal cancer. J. Clin. Oncol.21, 60-65.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Kalbfleisch, J.D., and Prentice, R.L. (1980)\nThe Statistical Analysis of Fail ure Time Data. New\nYork: John Wiley & Sons.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Kaplan, E.L., and Meier, P. (1958) Nonparametric\nestimation from incom plete observations. J. Am. Stat.\nAssoc.53,457\n-481.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Kerbel, R.S. (2001) Clinical trials of antiangiogenic\ndrugs: Opportunities, problems, and assessment of initial results.\nJ. Clin. Oncol.19,45S\n-51S.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Khan, M.K., Miller, M.W., Taylor, J., Gill, N.K., Dick, R.D., Van\nGolen, K., Brew, G.J., and Merajver, S.D. (2002) Radiotherapy and\nantiangiogenic TM in lung cancer. Neoplasia4, 164-170.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Lacroix, M., Abi-Said, D., Fourney, D.R., Gokaslan, Z.L., Shi, W.,\nDeMonte, F., Lang, F.F., McCutcheon, I.E., Hassenbusch, S.J., Holland, E.,\nHess, K., Michael, C., Miller, D., and Sawaya, R. (2001) A\nmultivariate analy sis of 416 patients with glioblastoma multiforme:\nPrognosis, extent of resection, and survival. J.\nNeurosurg.95,190\n-198.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Linder, M.C., and Hazegh-Azam, M. (1996) Copper\nbiochemistry and molecular biology. Am. J. Clin. Nutr.63,797S\n-811S.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Littman, M.L., Taguchi, T., and Shimizu, Y. (1963)\nAcceleration of growth of sarcoma 180 with pyridoxamine and retardation with\npenicillamine. Proc. Soc. Exp. Biol. Med.113,667\n-674.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Marsden, C.D. (1987) Wilson's disease. Q.\nJ. Med.248,959\n-966.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Matsubara, T., Saura, R., Hirohata, K., and Ziff, M.\n(1989) Inhibition of human endothelial cell proliferation in\nvitro and neovascularization in vivo by d-penicillamine.\nJ. Clin. Invest.83,158\n-167.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Netter, P., Bannwarth, B., Pere, P., and Nicolas, A.\n(1987) Clinical pharma cokinetics of d-penicillamine.\nClin. Pharmacokinet. 13,317\n-333.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Pan, Q., Kleer, C.G., van Golen, K.L., Irani, J., Bottema, K.M.,\nBias, C., De Carvalho, M., Mesri, E.A., Robins, D.M., Dick, R.D., Brewer,\nG.J., and Merajver, S.D. (2002) Copper deficiency induced by\ntetrathiomo lybdate suppresses tumor growth and angiogenesis.\nCancer Res.62,4854\n-4859.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Puduvalli, V.K., and Sawaya, R. (2000)\nAntiangiogenesis\u2014therapeutic strategies and clinical implications for\nbrain tumors. J. Neurooncol.50,189\n-200.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Redman, B.G., Esper, P., Pan, Q., Dunn, R.L., Hussain, H.K.,\nChenevert, T., Brewer, G.J., and Merajver, S.D. (2003) Phase II\ntrial of tetrathiomo lybdate in patients with advanced kidney cancer.\nClin. Cancer Res.9,1666\n-1672.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Schiff, D. (1996) Pneumocystis pneumonia in brain\ntumor patients: Risk factors and clinical features. J.\nNeurooncol.27,235\n-240.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Singh, G., Fries, J.F., Williams, C.A., Zatarain, E., Spitz, P.,\nand Bloch, D.A. (1991) Toxicity profiles of disease modifying\nantirheumatic drugs in rheumatoid arthritis. J.\nRheumatol.18,188\n-194.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Smith, D.B., and Gallagher, B.B. (1970) The effect of\npenicillamine on sei zure threshold. The role of pyridoxine. Arch.\nNeurol.23,59\n-62.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Sproull, M., Brechbiel, M., and Camphausen, K. (2003)\nAntiangiogenic therapy through copper chelation. Expert Opin. Ther.\nTargets7,405\n-409.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Strausak, D., Mercer, J.F., Dieter, H.H., Stremmel, W., and\nMulthaup, G. (2001) Copper in disorders with neurological\nsymptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res.\nBull.55,175\n-185.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B.,\nTaphoorn, M., Brandes, A.A., Cairncross, G., Lacombe, D., and Miri manoff,\nR.O. (2004) Concomitant and adjuvant temozolomide (TMZ) and\nradiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM).\nConclusive results of a randomized phase III trial by the EORTC Brain & RT\nGroups and NCIC Clinical Trials Group. J. Clin. Oncol.22 (14S), 2\n(abstract).","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Takano, S., Gately, S., Engelhard, H., Tsanaclis, A.M., and Brem,\nS. (1994) Suramin inhibits glioma cell proliferation in vitro and\nin the brain. J. Neurooncol.21,189\n-201.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Turecky, L., Kalina, P., Uhlikova, E., Namerova, S., and Krizko, J.\n(1984) Serum ceruloplasmin and copper levels in patients with\nprimary brain tumors. Klin. Wochenschr.62,187\n-189.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Turnlund, J.R., Scott, K.C., Peiffer, G.L., Jang, A.M., Keyes,\nW.R., Keen, C.L., and Sakanashi, T.M. (1997) Copper status of\nyoung men consum ing a low-copper diet. Am. J. Clin.\nNutr.65,72\n-78.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Weindruch, R., and Walford, R.L. (1982) Dietary\nrestriction in mice begin ning at 1 year of age: Effect on life-span and\nspontaneous cancer inci dence. Science215,1415\n-1418.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Westphal, M., Hilt, D.C., Bortey, E., Delavault, P., Olivares, R.,\nWarnke, P.C., Whittle, I.R., Ja\u0308a\u0308skela\u0308inen, J., and Ram, Z.\n(2003) A phase 3 trial of local chemotherapy with biodegradable\ncarmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant\nglioma. Neuro-Oncol.5,79\n-88.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Williams, S.R. (1993) Nutrition and Diet\nTherapy, 7th ed. St. Louis: Mosby-Year Book, Inc., pp.253\n-268.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Yoshida, D., Ikeda, Y., and Nakazawa, S. (1995) Copper\nchelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma\nmodel. Neurosurgery37,287\n-293.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Yoshii, J., Yoshiji, H., Kuriyama, S., Ikenaka, Y., Noguchi, R.,\nOkuda, H., Tsujinoue, H., Nakatani, T., Kishida, H., Nakae, D., Gomez, D.E.,\nDeLorenzo, M.S, Tejera, A.M., and Fukui, H. (2001) The\ncopper-chelating agent, trientine, suppresses tumor development and\nangiogenesis in the murine hepatocellular carcinoma cells. Int. J.\nCancer94,768\n-773.","DOI":"10.1002\/ijc.1537"},{"key":"key\n\t\t\t\t20171013081809_","doi-asserted-by":"crossref","unstructured":"Ziche, M., Jones, J., and Gullino, P.M. (1982) Role of\nprostaglandin E1 and copper in angiogenesis. J. Natl. Cancer\nInst.69,475\n-482.","DOI":"10.1002\/ijc.1537"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/7\/3\/246\/13066203\/NO007-03_04Brem.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T08:19:00Z","timestamp":1507882740000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article\/7\/3\/246\/1069726\/Phase-2-trial-of-copper-depletion-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,7,1]]},"published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1215\/s1152851704000869","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,7]]},"published":{"date-parts":[[2005,7,1]]}}}